These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9269551)

  • 1. Complete remission of extensive metastatic renal cancer following immunotherapy.
    Plowman PN; Costello J; O'Donoghue N
    Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 5. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.
    Spencer WF; Linehan WM; Walther MM; Haas GP; Lotze MT; Topalian SL; Yang JC; Merino MJ; Lange JR; Pockaj BA
    J Urol; 1992 Jan; 147(1):24-30. PubMed ID: 1729540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive nephrectomy in metastatic renal cancer.
    Flanigan RC
    Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy for advanced renal cell cancer].
    Schmidt S; Kunath F; Kroeger N
    Urologe A; 2015 May; 54(5):716-20. PubMed ID: 25987336
    [No Abstract]   [Full Text] [Related]  

  • 10. Present achievements in the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Debled M
    Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
    Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
    Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?
    Young RC
    N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy.
    Hayashi T; Miyagawa Y; Tsujimura A; Nonomura N; Minami M; Okuyama A
    Int J Urol; 2006 Jun; 13(6):805-8. PubMed ID: 16834666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
    J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy in metastatic cancer of the kidney].
    Escudier B
    Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.